-ssslipiodol development of a potential treatment for hcc from bench to bedside-ssslipiodol发展潜在的治疗肝细胞癌从基础研究到临床应用.pdfVIP

Hindawi Publishing Corporation International Journal of Molecular Imaging Volume 2012, Article ID 278306, 9 pages doi:10.1155/2012/278306 Research Article 188Re-SSS/Lipiodol: Development of a Potential Treatment for HCC from Bench to Bedside 1, 2, 3 ´ 1, 3 2, 3 1, 3 Nicolas Lepareur, Valerie Ardisson, Nicolas Noiret, and Etienne Garin 1 Centre Regional de Lutte Contre le Cancer Eugene Marquis, INSERM UMR-S 991, Avenue de la Bataille Flandres-Dunkerque, ´ ` CS 44229, 35042 Rennes, France 2 Ecole Nationale Superieure de Chimie de Rennes, CNRS UMR 6226, Avenue du General Leclerc, CS 50837, 35708 Rennes, France ´ ´ ´ 3 Universite Europeenne de Bretagne, 35000 Rennes, France ´ ´ Correspondence should be addressed to Nicolas Lepareur, n.lepareur@rennes.unicancer.fr Received 12 October 2011; Revised 8 December 2011; Accepted 13 December 2011 Academic Editor: John Humm Copyright © 2012 Nicolas Lepareur et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Hepatocellular carcinoma (HCC) is the 5th most common tumour worldwide and has a dark prognosis. For nonoperable cases, metabolic radiotherapy with Lipiodol labelled with β -emitters is a promising therapeutic option. The Comprehensive Cancer ` Centre Eugene Marquis and the National Graduate School of Chemistry o